Boehringer Ingelheim already had the FDA's "breakthrough" designation on idarucizumab, an antidote to its blockbuster anticoagulant Pradaxa. Now, the reversal agent has stepped on the agency's fast track, which cuts review time by four months.
Eli Lilly and Boehringer Ingelheim secured a recommendation from European regulators for their combination diabetes treatment, making for a likely continental approval in the coming months.
Newcomers showed off at this year's American Academy of Dermatology meeting, with more than one touting Stelara-beating data--and prepping the market for an all-out psoriasis war.
Nearly 250 workers at a closed Boehringer Ingelheim API facility in Virginia that had been told they might be able to hold on to their jobs have had their hopes dashed. The Chinese company that agreed to buy and expand the facility has decided to leave it closed until business improves.
Psoriasis has attracted a big pack of rival drug giants anxious to be in the lead with a new wave of better, targeted therapies for legions of patients. But a team of investigators at Rockefeller University say they just scored early-stage data on a new drug from Boehringer Ingelheim that promises to offer a potential cure with a more durable therapy.
India's patent office has revoked the patent of Boehringer Ingelheim on emphysema treatment Spiriva after a challenge from local firm Cipla.
Boehringer Ingelheim submitted U.S., European and Canadian applications for an antidote to its own Pradaxa, leading the way among companies developing treatments that reverse the effects of blockbuster next-generation anticoagulants.
Boehringer Ingelheim has put a hold on its Phase I work with a BACE inhibitor for Alzheimer's, marking the latest in a series of missteps for this category of therapeutics, which has emerged as one of the key arenas in the field.
Boehringer Ingelheim's global restructuring--prompted by the German pharma's sales struggle--is now manifesting itself in Connecticut, where the company is laying off staffers in Ridgefield.
Struggling with falling sales, Boehringer Ingelheim is trimming its workforce in Connecticut, which accounts for about 2,700 staffers altogether.